Founded in 1993, Greenstone LLC, a subsidiary of Pfizer, brought its generic version of medroxyprogesterone acetate to the contraceptive market. Unlike the original Depo-Provera, Greenstone's version gained popularity for being the affordable alternative. Yet, studies have shown that using it poses health risks.
Greenstone's marketing stressed its link to Pfizer and its quality. What wasn't clear was the potential to cause neurological risks. A March 2024 study in the British Medical Journal found that women using medroxyprogesterone acetate products, including Greenstone's generic, face a 5.6 times higher risk of meningioma.
Due to its cost-effectiveness, Greenstone's version has been prevalent in community health centers and university medical facilities. This wide distribution means thousands of women are getting these injections, and they are unaware of the brain tumor risks.
The investigations into Greenstone's medroxyprogesterone acetate have revealed several concerns:
The 2024 BMJ study found that, despite being generic, the active ingredient poses the same brain tumor risks as the brand-name version.
If you got Greenstone's medroxyprogesterone acetate injections and then developed meningioma, you might have a legal case. Our team at Atraxia Law has experience with cases involving dangerous drugs.
Given the case complexity, we focus on building strong claims. We base them on Greenstone's specific documentation and marketing practices. We have 35 years of expertise that can make the legal process easy for you. If you are deemed eligible, we will connect you with an attorney specializing in dangerous drug cases.
10 Minutes Over the Phone
*No fees unless compensation is obtained